Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
December 2011

Atypical Antipsychotics: Off-Label Uses
The use of second-generation antipsychotics for off-label indications is increasingly common but often unjustified by research.

Mifepristone for Psychotic Depression
In a double-blind trial, mifepristone (Mifeprex) augmentation was not found to be statistically different from placebo for the treatment of psychotic depression.

Reducing the Risk of Alzheimer Disease
Up to half of all cases of Alzheimer disease may be attributable to seven modifiable risk factors.

Allergic Reactions to Asenapine
Asenapine can cause potentially lethal allergic reactions, sometimes at an initial dose.

In Brief
Armodafinil and Quetiapine Interact in Patients with Schizophrenia; fMRI Reveals Changes in Neural Circuitry Involved in Depression

Depression in Dementia: No Benefit from Two Antidepressants
New data casts doubt on the use of antidepressants to treat depression in patients with dementia.

CME 2011
CME 2011 Reminder

Year's End
Dr. Gelenberg's end-of-year editorial and holiday message.

INDEX
2011 Index

Atypical Antipsychotics: Off-Label Uses

December 2011

In the United States, second-generation antipsychotic drugs are labeled by the FDA for the treatment of schizophrenia, bipolar disorder, and in some circumstances, depression. The FDA has recently granted approval for quetiapine (Seroquel) and aripiprazole (Abilify) as augmentation therapy in major…

To view the rest of this article, please: